e l f Beauty Inc vs Edwards Lifesciences Corporation Common Stock — how do they compare? e l f Beauty Inc trades at $105.97 (market cap $6.20B), while Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 8× e l f Beauty Inc's market cap, and Edwards Lifesciences Corporation Common Stock is more actively traded (3,508,027 versus 1,301,240). Which is the better fit depends on your goals.
| ELF | EW | |
|---|---|---|
Market Cap | $6.20B | $49.44B |
Volume | 1,301,240 | 3,508,027 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $95.18 |
52-Week Low | $49.57 | $72.65 |
Typical Hold Time | 25 Days | — |
Enterprise Value | $6.78B | $45.90B |
Signals from Pluang's Aura AI — not financial advice
ELF trades at $105.03, up 2.18% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong revenue growth, with 2025 revenue at $1.31B and net income of $112.09M, though 2026 projections show margin compression. Recent expansion includes the rhode brand launch in Europe via Sephora and marketing initiatives like the 'Mirror Mix' album.
The outlook is mixed: robust growth and analyst support (48% buy ratings) contrast with high valuation (P/E 107.17) and competitive pressures. Key risks include execution of international expansion and sustained profitability amid increased spending. The stock's current price sits above the consensus target of $95.91, suggesting limited near-term upside.
No Aura AI signal available yet.
Trailing returns across standard periods
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →